← All trials
NCT03181451
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 14, 2017
- Primary completion
- Sep 28, 2017
- Completion date
- Dec 28, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 36
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Shield TherapeuticsLead sponsor
- Medpace, Inc.Collaborator
- Shield TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.